CASE PRESENTATION OF MUCORMYCOSIS IN DIABETIC PATIENT AND APPROACH TO ITS MANAGEMENT IN A TERTIARY CARE CENTRE AUTHOR -DR MANOJ GUPTA GUIDED BY - DR SUDHAKAR VAIDYA

1st year Resident

Department of ENT, R.D. GARDI Medical College, Ujjain, M.P

Professor and Head

INTRODUCTION

- Mucormycosis (phycomycosis, zygomycosis) is a rare opportunistic angioinvaisve fungal infection caused by fungi belonging to the Mucorales order and the Mucoraceae family
- ➤.Mucormycosis is transmitted by inhalation, ingestion or direct inoculation of spores and was first described by Furbinger in 1876.
- ➤ Predisposing factors include immunocompromised states like uncontrolled diabetes, lymphomas and leukemias, renal failure, organ transplant, long term corticosteroid and immunosuppressive therapy, cirrhosis, burns and Acquired Immuno Deficiency Syndrome (AIDS).
- ➤In diabetics. the acidic pH produces more free iron by reducing its binding to transferrin which impairs neutrophilic function thus producing suitable conditions for fungal multiplication.
- Mucormycosis infection in diabetes may result from tooth extraction, intramuscular injections and ophthalmic surgeries.
- Rhinocerebral Mucormycosis is an infection of paranasal sinus origin, caused by inhalation of Mucor spores and their spread to orbit or the brain.
- Successful management of this fatal infection requires early identification of the disease, aggressive and prompt medical and surgical interventions to prevent high morbidity and mortality associated with this disease process.

We report here with a case of rhino orbital mucormycosis in a diabetic patient



PAIN AND
SWELLING OVER
NOSE AND RIGHT
SIDE OF FACE AND
BLACKENING
NEAR RIGHT
MEDIAL






BLACK
NECROTIC
ESCHAR WITH
SURROUNDING
EDEMA ON
HARD PALATE.

ENDOSCOPIC
IMAGE OF BLACK
CRUST ON THE
RIGHT
MAXILLARY
SINUS


CASE REPORT WITH INVESTIGATIONS

- A 65 year old male patient, k/c/o diabetes mellitus type 2 and hypertension since 15 years, came to our outpatient department with chief complaints of pain and swelling on right side of nose, face and periorbital region since 15 days.
- > O/E FACE -diffuse swelling over the right middle third of face extending from the lateral aspect of the nose to the inner canthus of the eye and also right periorbital region with blackish pigmentation near right medial canthus.
- > On palpation, the swelling was soft in consistency, non tender with no local rise of temperature.
- > NASAL EXAMINATION Anterior rhinoscopy showed black crusting in right nasal cavity
- > ORAL CAVITY black eschar over hard palate.
- > OPHTHALMIC EXAMINATION-right pupil was non reactive
- > KOH MOUNT revealed numerous broad aseptate fungal hyphae
- > CT PNS showed swelling in right side
- of face. soft tissue density with air pockets in right nasal cavity, maxillary, sphenoidal, ethmoidal and frontal sinuses and appears to be infilterating the inferior wall of right orbit.
- MRI BRAIN, ORBIT AND PNS showed right maxillary, ethmoidal and sphenoidal sinusitis, absorbed right middle and inferior turbinates, infero medial wall of orbit fuzzy, findings in favour of rhinoorbital mycormucosis.



- > Provisional diagnosis of mucormycosis of the maxilla was made
- ➤ **Differentials** includes neoplasia, aspergillosis, osteomyelitis, chronic granulomatous infection, and deep fungal infections.

On lab investigations, elevated blood sugar levels and neutrophilic lecocytosis were found.



Histopathological report-BROAD
ASEPTATE OBTUSELY BRANCHED
FUNGAL HYPHAE WITH
ANGIOINVASION SUGGESTIVE OF
INVASIVE MUCORMYCOSIS.

MANAGEMENT

➤ **Procedure** -Surgical debridement was done by removal of black crusting with microdebrider from right nasal cavity and septum then inferior turbinectomy with partial middle turbinectomy, right medial maxillectomy with mega antrostomy of right maxillary sinus, orbital decompression were done by removing lamina papyracea, preorbita and fat, amphotericin ointment put in right nasal cavity.

endoscopic suction and clearance in every 2 days with daily nasal douching.

- ➤ Treatment INJ. LIPOSOMAL AMPHOTERICIN B 50 mg/ kg (6 vials) in 500 ml 5 % dextrose.
- inj Zilamac 1 gm i/v 12 hourly
- tab Posaconazole 100 mg 12 hourly

and supportive treatment

check CBC in every 2 days and daily monitoring of serum sodium, potassium and creatinIne,

Daily physician check up for raised blood sugar levels and high BP.

DISCUSSION

- ➤ Rapid extensive debridement of the whole necrotic tissue is key for faster healing of this condition and it reduces the fungal load and halt the progression of disease.
- Antifungal must be empirically started as the disease has a fast progression rate. Medical treatment of Liposomal Amphotericin B has led to a survival rate of upto to 72%.
- European guideline recommends dosage of 5mg/kg body weight with total accumulated dose of 2.5 to 3g of Amphotericin B.[2]
- The universal risk factor is Diabetes. According to Global guideline for the diagnosis and management of mucormycosis, any diabetic patient with facial pain, sinusitis, proptosis, ophthalmoplagia, is at risk of mucormycosis and warrants a CT or MRI of the head.
- > Surgical debridement with clean margins should be achieved in parallel to antifungal treatment.
- Liposomal amphotericin B is preferred compared to the conventional Amphotericin B as it is better associated with fever breakthrough fungal infection,less infusion related toxicity, and less nephrotoxicity. [3]

CONCLUSION

In conclusion, early diagnosis, aggressive surgical debridement, injectable liposomal amphotericin B, topical Amphotericin therapy, control of underlying comorbidities and other supportive measure with close monitoring can remarkably achieve a low mortality in patients with sinonasal mucormycosis.

Reference

- 1. Mbarek C, Zribi S, Khamassi K, Hariga I, Ouni H, Ben Amor M, Ben Gamra O, El Khedim A. Rhinocerebral mucormycosis: five cases and a literature review. B-ent. 2011 Jan 1;7(3):
- 2. Aani P, Aandu T. Revised Treatment protocol for patients with Mucormycosis infection, chennai: chennai Government of Tamilnadu; 2021.

POST OPERATIVE

DAY 3 INVASIVE

LESION SEEN ON

RIGHT MEDIAL

CANTHUS AND

LOWER LIP

- 3. Udayani LA, Daminda DA, Rupasinghe RT. A protocol for management of Rhino-cerebral Mucormycosis. Ceylon Journal of Otolaryngology. 2019 Dec 28;8(1).
- 4. Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, Pappas P, Seibel N, Greenberg RN, Dummer S, Schuster M. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia.

 New England Journal of Medicine. 1999 Mar 11;340(10):764-71.